CLEVELAND, July 10, 2018 (GLOBE NEWSWIRE) — Innovest Global Inc. (OTC Markets:IVST) (the “Company” or “Innovest”), a diversified holding company with operations in commercial and industrial products and services, energy, and health services, closed June with it’s third straight record monthly sales achievement, at $409K from it’s Commercial & Industrial Division.
“We’re just getting started,” said Dan Martin, Innovest’s Chief Executive Officer. “Our Commercial & Industrial Division is less than six months old and is already attracting significant clients, and significant potential partners.” Damon Mintz (Division President) led the Innovest team in defining the ‘Source of Strength Doctrine’ which has helped the company achieve more than 10% organic growth, month over month this year. That organic growth is a primary attraction for acquisition candidates.
Other June activities include:
- Engagement of Hayden IR. Hayden IR is a highly regarded investor relations consulting firm known for its ability to connect underfollowed and undervalued emerging growth companies with sophisticated institutional investors, buy-side and sell-side analysts, retail brokerage firms and accredited individual investors. Leveraging decades of cumulative experience, Hayden IR develops strategies to help clients effectively communicate with the investment community and works to increase their exposure through targeted outreach and transparent positioning. Hayden IR helps public companies deliver the right message to the right audience. Over time, Hayden IR helps its clients navigate up the Wall Street value chain and to help them secure a reasonable valuation by broadening their audience, expanding institutional ownership and ensuring clear, consistent communication with the public.
- A new corporate website. The new website sets the stage for forthcoming developments, as Innovest continues to navigate an extensive acquisition pipeline, expand its leadership team, solidify corporate objectives, and strengthen operations. The new website and management philosophies illustrate the identity Innovest has grown into since launching the acquisition strategy just nine months ago.
- Byram Healthcare $650K+ Fortune 500 Division contract kick-off. “The Innovest team is highly professional, does an incredible job for us at the right price, and takes our business as seriously as we do,” said Perry Bernocchi, Chief Executive Officer of Byram Healthcare. “After reviewing all proposals and interviewing all the companies that submitted bids, we found them to be the ideal partner to speak with our customers and service their needs. To our customers, they are part of the Byram team, and they’ve proven we can rely on them to be a proud part of our family.” Byram is the single largest Innovest sales contract to date.
The company is also finalizing its 2017 audit and plans to apply for uplist to OTCQB. Additionally, the Biotech & Health Services division launch is in final paperwork stage and will be announced soon. “We’re not only finalizing the StemVax transaction previously announced as a ‘Letter of Intent’, but also working on some very promising unrelated projects,” said Division President, Dr. Dwain Morris-Irvin. “The Innovest business model has been a magnet for exciting prospects, and we are very diligently putting the framework to good use and exploring all opportunities.”
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets:IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and have announced a Biotechnology & Health Sciences Division that will launch in 2018.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.